October 24: The Week in Cancer News
COVID vaccines may improve immunotherapy effects, and a drug combination reduces the risk for death in bladder cancer.
COVID vaccines may improve immunotherapy effects, and a drug combination reduces the risk for death in bladder cancer.
In October 2025, AACR's journals editors highlighted studies on the anticancer function of an Alzheimer’s-related protein, small-molecule-drug conjugates, and more.
The FDA approved the BCMA-targeted antibody-drug conjugate belantamab mafodotin-blmf as part of a combination therapy for adults with refractory or recurrent multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved belantamab mafodotin-blmf...
The AACR Conference on the Science of Cancer Health Disparities explored the field's evolving landscape, including funding and and long-term impact.
Frank McCormick, PhD, FAACR, reflected on a career chasing the notorious RAS oncogene that earned him the inaugural Stephenson Global Prize.
The psychological toll of cancer can have an impact on patients’ mental health and put them at an increased risk of harm.
Older people with multiple myeloma can receive a less toxic drug regimen, and the FDA approves an immunotherapy for people with high-risk skin cancer.
The FDA approved cemiplimab-rwlc as an adjuvant therapy for patients with cutaneous squamous cell carcinoma at high risk of recurrence. The U.S. Food and Drug Administration (FDA) has approved cemiplimab-rwlc (Libtayo) for use after...
Patients with cancer in rural or high-poverty areas were associated with the most significant improvements in five-year survival. In 2014, a provision under the Patient Protection and Affordable Care Act (ACA) took effect, allowing...
Widespread uptake of HPV vaccine linked to reduced rates of cancer-causing infection in all, and radiation prevents recurrence in locally advanced bladder cancer.